0
0
A recent study published in JAMA Network Open reveals a significant proliferation of gray market psilocybin sales across major Canadian urban centers, despite its illegal status for recreational use. Researchers found that as of May 2024, 57 psilocybin stores were operating in over a third (35.7%) of major Canadian urban areas, with the vast majority (96.5%) located in Ontario and British Columbia.
The study, led by researcher Jenna Matsukubo, aimed to document the existence and locations of these stores, as well as analyze the health claims and warnings they provided. Data collection spanned from November 2023 to May 2024, revealing a dynamic market with stores opening and closing frequently.
The researchers identified a wide range of psilocybin products available, including dried mushrooms, microdosing capsules, and edibles such as chocolates and gummies. Notably, nearly two-thirds of the stores sold products mimicking popular brand-name snacks.
A concerning finding was the prevalence of unsubstantiated health claims. Approximately 86% of the stores’ websites contained claims related to mental health, substance use, wellness, and physical health, often with limited or no scientific backing. Claims included reductions in anxiety and depression, decreased cravings for alcohol and nicotine, and improvements in focus and creativity.
“We were surprised by the broad omission of potentially better-established risks, such as cautioning use by people with a history of bipolar disorder or mania, or psychosis or schizophrenia,” said co-author Dr. Daniel Myran.
While some stores provided warnings about potential hallucinations and “bad trips,” only a small percentage cited published scientific evidence.
“In the absence of regulation and enforcement, there are health claims being made that would need to meet the standards of other products and therapeutics. This suggests that some sort of federal or provincial action should be taken,” Myran stated.
The study highlights the gap between the illegal status of psilocybin and its increasing accessibility through gray market retailers. Experts emphasize the need for vigilance and potential regulatory action to address the risks associated with these unregulated sales.
“It’s extremely unlikely that any sort of public ad or harm reduction campaign is going to be successful in creating enough awareness around these drugs for them to be liberally sold as is online and in dispensaries,” said Dr. Kyle Greenway.
The study underscores the rapid evolution of this market and the challenges it poses for public health and regulatory bodies.
Disclaimer: The information provided in this article is for informational purposes only and does not constitute medical advice. The sale and possession of psilocybin for recreational use are illegal in Canada. Readers are advised to consult with a qualified healthcare professional before making any decisions related to their health or treatment. This article does not endorse or promote the use of illegal substances. The findings of the study mentioned should be interpreted within the context of the study’s limitations.
